Table of Contents Table of Contents
Previous Page  20 / 25 Next Page
Information
Show Menu
Previous Page 20 / 25 Next Page
Page Background

Inmunoterapia

Anti PD1

Pembrolizumab

Nivolumab

Anti PDL1

Avelumab

Anti CTLA4

Ipilimumab